Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, CanadaT T Hoang, Greg Rosenfeld, Jacqueline Reid et al.|Journal of the Canadian Association of Gastroenterology|2024Cited by 5